

IntelGenx Technologies Corp.  
Form 8-K  
November 14, 2011

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**November 11, 2011**  
*Date of Report (Date of Earliest Event Reported)*

**IntelGenx Technologies Corp.**  
*(Exact Name of Registrant as Specified in its Charter)*

<b>Delaware</b> <i>(State or other jurisdiction of incorporation)</i>	<b>000-31187</b> <i>(Commission File Number)</i>	<b>87-0638336</b> <i>(IRS Employer Identification No.)</i>
<b>6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9</b> <i>(Address of principal executive offices) (Zip Code)</i>		

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01 Other Events - News Release**

**IntelGenx Announces FDA Approval of its High Dose Anti-Depressant CPI-300**

IntelGenx Corp. ("IntelGenx", or the Company ), today announced that the U.S. Food and Drug Administration (FDA) has approved IntelGenx' lead product, CPI-300, for patients with Major Depressive Disorder. CPI-300 is a novel, high-strength formulation of Bupropion hydrochloride (HCl), the active ingredient in Wellbutrin XL. CPI-300 is the only single dose 450 mg formulation of Bupropion HCl approved by the FDA.

Exhibit	Description
<u>99.1</u>	<u>Press Release</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: November 11, 2011

By: */s/ Horst Zerbe*  
Horst G. Zerbe  
President and Chief  
Executive Officer